TrialAssure Releases TrialAssure LINK
TrialAssure has announced the release of TrialAssure LINK software for the development, review, translation and publishing of plain language, or lay summaries.
Key features of LINK include the ability to:
- Create ready-to-review lay summaries through preconfigured data feeds
- Manage workflows by serving as a comprehensive project management solution
- Maximize re-use of clinical trial data, speeding the process and enhancing data integrity
- Adhere to best practices using lay term glossaries, readability analytics, and auto-generated graphics, charts, and images
- Apply and review translations consistent with languages spoken by clinical trial participants
- Meet global transparency demands
TrialAssure LINK is a core application within The Ultimate Transparency Suite along with existing applications that include TrialAssure REGISTRY, TrialAssure ANONYMIZE, and TrialAssure BEACON.
For more information, click here.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
